About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
2020 ASCO Virtual Direct™ Highlights
Boston
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
St. Louis
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
Basic Science
Jacksonville
Breast
Hematologic Oncology
Lung
GI
GU
GYN
Skin
Head&Neck
Basic Science
Philadelphia
GI
GU
Lung
Skin
Hematologic Oncology
Breast
Supportive/Palliative Care
Head&Neck
GYN
Denver
Breast
Hematologic Oncology
Lung
GU
Skin
GYN
Head&Neck
Basic Science
San Francisco
Breast
Lung
GU
Hematologic Oncology
Skin
GI
GYN
Head&Neck
Business
Las Vegas
GI
GU
Hematologic Oncology
Skin
Lung
Head&Neck
GYN
Business
San Juan
Breast
GI
Hematologic Oncology
Skin
GYN
Basic Science
Head and Neck
Supportive and Palliative Care
Business
Events
Lung
14:06
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on SCLC: Anti-PD-1/L1 Staple for 1st L Treatment (Atezolizumab and Durvalumab + EP Improve OS, Pembro Improve PFS) & Safety, Tolerability and Efficacy of Liposomal Irinotecan in 2nd L Setting
FEATURING
Jason Porter
143 views
July 13, 2020
12:25
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Metastatic NSCLC w/o Actionable Mutations: Chemo-Free Option With Nivo + Ipi, Nivo + Ipi + Chemo Safe and Tolerable & Data on Novel Anti-TIGIT Agent Tiragolumab + Atezo
FEATURING
Jason Porter
300 views
July 15, 2020
1
09:53
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Targeted Therapies for NSCLC: Clinical Activity of T-Dxd in HER2 Mutated NSCLC & Feasibility of Osimertinib/Gefitinib Combination in EGFR-mutated Disease
FEATURING
Jason Porter
289 views
July 13, 2020
2
